Clinical Trial Update: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata [Phase 3]

View source ↗

Summary

This document reports an ongoing Phase 3 clinical trial of baricitinib (LY3009104) in children aged 6 to under 18 with alopecia areata, which is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia
• Alopecia Areata

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Areata Alopecia, Alopecia | Phase 3 | Status: RECRUITING